The "Drug Biochemistry" working group researches the use of small molecules and natural substances, including monoclonal antibodies, for the treatment of various diseases. The focus is on inhibitors of enzymes and the degradation of misfolded proteins as well as pathomechanisms of neurodegenerative and inflammatory diseases. The various projects are carried out in close cooperation with the Center for Natural Product-Based Therapeutics (ZNT) at Anhalt University of Applied Sciences and the Fraunhofer IZI-MWT in Halle, which is headed by Prof. Schilling.
© AG Prof. Schilling
Head of department
Isolation and characterization of active substances (enzyme inhibitors and protein active substances)
- Heterologous expression, purification and enzyme kinetic characterization of enzymes that act as drug targets; crystallization and structure elucidation of protein complexes, isolation and humanization of monoclonal antibodies for diagnostic and therapeutic applications; synthesis of active ingredients (medicinal chemistry)
- Role of post-translational modifications in the development of diseases, focus on protein folding diseases and infections
Diagnostics (companion diagnostics)
- Immunochemical methods (ELISA) to detect the effect of potential drugs, analytical methods to detect active substances in the organism - LC/MS, MALDI imaging, FACS analysis and immunohistochemistry; focus on companion diagnostics
